Rwanda Military Hospital
Kigali, 0000, Rwanda
NCT Number: NCT02281461
The PrePex is a WHO prequalified medical device for adult male circumcision for HIV prevention. The Government of Rwanda was the first country to implement the PrePex and acts as the leading Center of Excellence providing training and formal guidelines.
In support of efforts to scale up male circumcision, readily available data have been applied to estimate the potential cost and impact of scaling up medical MC services in Rwanda to reach 80 percent of adult, children and newborn males by 2015. Infant and children male circumcision ensures that the wound will be healed before sexual activity begins, and thus reduces the risk of HIV transmission during healing period.
Looking for future studies?
Notify Me5 day–10 year
Male
Interventional
Not applicable
Kigali, 0000, Rwanda
The American Academy of Pediatrics (AAP) published in August 2012 a technical report and a policy statement, "Evaluation of current evidence indicates that the health benefits of new-born male circumcision outweigh the risks; furthermore, the benefits of newborn male circumcision justify access to this procedure for families who choose it. Specific benefits from male circumcision were identified for the prevention of urinary tract infections, acquisition of HIV, transmission of some sexually transmitted infections, and penile cancer. Male circumcision does not appear to adversely affect penile sexual function/sensitivity or sexual satisfaction. It is imperative that those providing circumcision are adequately trained and that both sterile techniques and effective pain management are used. Significant acute complications are rare."
The primary objective of the study was to assess the safety and efficacy of the PrePex device among healthy early infant and children males scheduled for voluntary circumcision. The study consisted of 2 phases:
Phase I included infants age 5-33 days Phase II included children age 4-10 years.
The study examined the feasibility of performing PrePex circumcision on early infants and children male population.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Male Circumcision
Time frame: 2 weeks
Safety by means of the following parameters: Moderate and Major Clinical adverse events and device-related incidents.
Time frame: 2 weeks
Glans fully exposed (full circumcision)
Time frame: 2 weeks
Rate of foreskin dilations and adhesion separations
Time frame: 2 weeks
Time to device detachment
Time frame: 2 weeks
Time to complete healing
Time frame: 2 weeks
Rate of expected side effects
Time frame: 2 weeks
Rate of pain / discomfort
Time frame: 2 weeks
Rate of voiding
Ministry of Health, Rwanda
Other Gov
A Feasibility Study of PrePex Device for Infants and for Children, When Performed on Early Infants and Children Male Population by Physicians
Acronym: RMC-06
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06073145
Brain Diseases, Brain Injuries
San Diego, California, United States
View Trial DetailsNCT03823209
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cleveland, Ohio, United States
View Trial DetailsNCT05664802
Acquired Immunodeficiency Syndrome, Behavior
Flagstaff, Arizona, United States
View Trial DetailsNCT05609513
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Kampala, Uganda
View Trial Details